All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On April 30th, the U.S. Food and Drug Administration (FDA) hosted a webinar about conducting clinical trials during the COVID-19 outbreak. Jacqueline Corrigan-Curay and John Concato, both from the Office of Medical Policy, reviewed the crucial parts from the recently updated FDA guidance on conduct of clinical trials of medical products during COVID-19 public health emergency for sponsors, investigators and institutional review boards (IRBs). This article summarizes the key messages.
This guidance is built around three priorities:
It is important to note that this is general guidance. Particular situations with regard to the study population, investigational product, and trial phase or endpoint may require consultation with the appropriate FDA review division.
The first question that needs to be addressed is: should sponsors stop their trial?
The responsible party for the trial will also need to evaluate alternative procedures to ensure effective data collection and monitoring (e.g., videoconferencing, sending samples to local laboratories, remote access to the patient's file).
Other important recommendations from the FDA are:
As a final note, the agency is expecting many protocol deviations due to this international public health emergency, but it will be flexible where appropriate.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox